Hana Biosciences Begins Marqibo Trial

Hana Biosciences has begun dosing in a Phase II trial of Marqibo in patients with metastatic malignant uveal melanoma.

The primary objective of the study is to assess the efficacy of Marqibo (vincristine sulfate injection, Optisome). Secondary objectives are to assess the safety and antitumor activity of the drug as determined by response duration, time to progression and overall survival.

The trial is supported by data from a Phase I trial in patients with metastatic melanoma originating in the eye. In that study, an objective response rate of 13 percent and stable disease rate of 20 percent were achieved in 15 patients, Hana said.